Loading...
•
Sep 30, 2021
Onconova Q3 2021 Earnings Report
Announced financial results for the third quarter of 2021 and provided a business update.
Key Takeaways
Onconova Therapeutics reported a net loss of $3.5 million, or $0.22 per share, for the third quarter of 2021. Cash and cash equivalents were $59.4 million as of September 30, 2021.
Progress during the third quarter has Onconova on track to achieve milestones across its pipeline.
Phase 1 studies of narazaciclib are on track to identify a recommended Phase 2 dose in the first half of 2022 and then initiate a Phase 2 safety and efficacy study in the second half.
Encouraging data reported from the Phase 1/2a investigator-initiated study of oral rigosertib plus nivolumab in advanced KRAS+ NSCLC.
An additional data update from the rigosertib study is expected in 2022, and an additional IIS evaluating rigosertib in combination with anti-PD-1 therapy in malignant melanoma will begin in the first half of next year.
Forward Guidance
Onconova believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations for more than two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...